ARTICLE | Product Development
COVID-19 roundup: Lilly joins NIH’s adaptive trial; plus Foresee, Congress, ASCO, BMS, Otsuka, EC, Terumo-Marker
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 11, 2020 1:29 AM UTC
Updated on Apr 11, 2020 at 1:50 AM UTC
Eli Lilly’s rheumatoid arthritis drug Olumiant baricitinib has become the second treatment added to NIH’s COVID-19 master protocol, joining Gilead’s remdesivir. Separately, U.S. representatives called on FDA to ensure diagnostics are accurate, and ASCO launched a registry to track how cancer patients during the pandemic.
NIH’s Adaptive COVID-19 Treatment Trial (ACTT) is testing novel therapies for the infection. The JAK inhibitor will start testing this month in the U.S., with a planned expansion to European and Asian sites. Eli Lilly and Co. (NYSE:LLY) said data from the NIH trial’s Olumiant arm should be available in about two months (see “Master Protocols Present Systemic Path Forward”)...